" class="no-js "lang="en-US"> Wendy Pinson - Medtech Alert
Saturday, December 02, 2023

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Wendy Pinson | Pharmtech Focus

Wendy Pinson

About Wendy Pinson

Highly motivated research professional with 14 years’ experience in the clinical research industry delivering record breaking growth through exceptional management. Meticulous with managing clinical operations across multiple therapeutic areas, including Oncology, Rare Disease, GI, Infectious Disease, Autoimmune, OB/GYN, and many more. I am truly passionate about seeing new therapies safely come to market while providing the best oversight for my team.

Related Story

Clinical Trials

 Vial Has Added NEXT Oncology

Vial Has Added NEXT Oncology, a Global Network of Phase I Cancer Research Centers, to their Preferred Site Network

November 22 2022

Vial has added NEXT Oncology to their Preferred Site Network (PSN). Founded by renowned oncologist Dr. Anthony W. […]